Celecoxib use and circulating oxylipins in a colon polyp prevention trial

Jessica A. Martinez, Jun Yang, Betsy C. Wertheim, Denise Roe, Alexander Schriewer, Michael P Lance, David S Alberts, Bruce D. Hammock, Patricia A. Thompson

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Drugs that inhibit cyclooxygenase (COX)-2 and the metabolism of arachidonic acid (ARA) to prostaglandin E2 are potent anti-inflammatory agents used widely in the treatment of joint and muscle pain. Despite their benefits, daily use of these drugs has been associated with hypertension, cardiovascular and gastrointestinal toxicities. It is now recognized that ARA is metabolized to a number of bioactive oxygenated lipids (oxylipins) by cyclooxygenase (COX), lipoxygenase (LOX), and cytochrome P450 (CYP450) enzymes. Currently, the contribution of individual variability in ARA metabolism in response to the COX-2 inhibitors and potential adverse effects remains poorly understood. Using patient samples from the randomized, placebo-controlled phase III selenium/celecoxib (Sel/Cel) trial for the prevention of colorectal adenomatous polyps, we analyzed plasma concentrations of 74 oxylipins in a subset of participants who received celecoxib (n = 90) or placebo (n = 95). We assessed the effect of celecoxib (with and without low dose aspirin) on circulating oxylipins and systolic blood pressure (SBP). Individual CYP450- and LOX- but not COX-derived metabolites were higher with celecoxib than placebo (P<0.05) and differences were greater among non-aspirin users. LOX derived 5- and 8-HETE were elevated with celecoxib and positively associated with systolic blood pressure (P = 0.011 and P = 0.019 respectively). 20-HETE, a prohypertensive androgen-sensitive CYP450 metabolite was higher with celecoxib absent aspirin and was positively associated with SBP in men (P = 0.040) but not women. Independent of celecoxib or aspirin, LOX derived metabolites from ARA were strongly associated with SBP including 5- and 8-HETE. These findings support oxylipins, particularly the ARA LOX-derived, in blood pressure control and indicate that pharmacologic inhibition of COX-2 has effects on LOX and CYP450 ARA metabolism that contribute to hypertension in some patients.

Original languageEnglish (US)
Article numbere0196398
JournalPLoS One
Volume13
Issue number4
DOIs
StatePublished - Apr 1 2018

Fingerprint

Celecoxib
Oxylipins
oxylipins
lipoxygenase
Polyps
arachidonic acid
colon
prostaglandin synthase
Lipoxygenase
Colon
Blood pressure
systolic blood pressure
Arachidonic Acid
Blood Pressure
Cytochrome P-450 Enzyme System
cytochrome P-450
aspirin
placebos
Metabolites
Metabolism

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Martinez, J. A., Yang, J., Wertheim, B. C., Roe, D., Schriewer, A., Lance, M. P., ... Thompson, P. A. (2018). Celecoxib use and circulating oxylipins in a colon polyp prevention trial. PLoS One, 13(4), [e0196398]. https://doi.org/10.1371/journal.pone.0196398

Celecoxib use and circulating oxylipins in a colon polyp prevention trial. / Martinez, Jessica A.; Yang, Jun; Wertheim, Betsy C.; Roe, Denise; Schriewer, Alexander; Lance, Michael P; Alberts, David S; Hammock, Bruce D.; Thompson, Patricia A.

In: PLoS One, Vol. 13, No. 4, e0196398, 01.04.2018.

Research output: Contribution to journalArticle

Martinez, JA, Yang, J, Wertheim, BC, Roe, D, Schriewer, A, Lance, MP, Alberts, DS, Hammock, BD & Thompson, PA 2018, 'Celecoxib use and circulating oxylipins in a colon polyp prevention trial', PLoS One, vol. 13, no. 4, e0196398. https://doi.org/10.1371/journal.pone.0196398
Martinez, Jessica A. ; Yang, Jun ; Wertheim, Betsy C. ; Roe, Denise ; Schriewer, Alexander ; Lance, Michael P ; Alberts, David S ; Hammock, Bruce D. ; Thompson, Patricia A. / Celecoxib use and circulating oxylipins in a colon polyp prevention trial. In: PLoS One. 2018 ; Vol. 13, No. 4.
@article{32e601a0450e482fb7436b469993facf,
title = "Celecoxib use and circulating oxylipins in a colon polyp prevention trial",
abstract = "Drugs that inhibit cyclooxygenase (COX)-2 and the metabolism of arachidonic acid (ARA) to prostaglandin E2 are potent anti-inflammatory agents used widely in the treatment of joint and muscle pain. Despite their benefits, daily use of these drugs has been associated with hypertension, cardiovascular and gastrointestinal toxicities. It is now recognized that ARA is metabolized to a number of bioactive oxygenated lipids (oxylipins) by cyclooxygenase (COX), lipoxygenase (LOX), and cytochrome P450 (CYP450) enzymes. Currently, the contribution of individual variability in ARA metabolism in response to the COX-2 inhibitors and potential adverse effects remains poorly understood. Using patient samples from the randomized, placebo-controlled phase III selenium/celecoxib (Sel/Cel) trial for the prevention of colorectal adenomatous polyps, we analyzed plasma concentrations of 74 oxylipins in a subset of participants who received celecoxib (n = 90) or placebo (n = 95). We assessed the effect of celecoxib (with and without low dose aspirin) on circulating oxylipins and systolic blood pressure (SBP). Individual CYP450- and LOX- but not COX-derived metabolites were higher with celecoxib than placebo (P<0.05) and differences were greater among non-aspirin users. LOX derived 5- and 8-HETE were elevated with celecoxib and positively associated with systolic blood pressure (P = 0.011 and P = 0.019 respectively). 20-HETE, a prohypertensive androgen-sensitive CYP450 metabolite was higher with celecoxib absent aspirin and was positively associated with SBP in men (P = 0.040) but not women. Independent of celecoxib or aspirin, LOX derived metabolites from ARA were strongly associated with SBP including 5- and 8-HETE. These findings support oxylipins, particularly the ARA LOX-derived, in blood pressure control and indicate that pharmacologic inhibition of COX-2 has effects on LOX and CYP450 ARA metabolism that contribute to hypertension in some patients.",
author = "Martinez, {Jessica A.} and Jun Yang and Wertheim, {Betsy C.} and Denise Roe and Alexander Schriewer and Lance, {Michael P} and Alberts, {David S} and Hammock, {Bruce D.} and Thompson, {Patricia A.}",
year = "2018",
month = "4",
day = "1",
doi = "10.1371/journal.pone.0196398",
language = "English (US)",
volume = "13",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "4",

}

TY - JOUR

T1 - Celecoxib use and circulating oxylipins in a colon polyp prevention trial

AU - Martinez, Jessica A.

AU - Yang, Jun

AU - Wertheim, Betsy C.

AU - Roe, Denise

AU - Schriewer, Alexander

AU - Lance, Michael P

AU - Alberts, David S

AU - Hammock, Bruce D.

AU - Thompson, Patricia A.

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Drugs that inhibit cyclooxygenase (COX)-2 and the metabolism of arachidonic acid (ARA) to prostaglandin E2 are potent anti-inflammatory agents used widely in the treatment of joint and muscle pain. Despite their benefits, daily use of these drugs has been associated with hypertension, cardiovascular and gastrointestinal toxicities. It is now recognized that ARA is metabolized to a number of bioactive oxygenated lipids (oxylipins) by cyclooxygenase (COX), lipoxygenase (LOX), and cytochrome P450 (CYP450) enzymes. Currently, the contribution of individual variability in ARA metabolism in response to the COX-2 inhibitors and potential adverse effects remains poorly understood. Using patient samples from the randomized, placebo-controlled phase III selenium/celecoxib (Sel/Cel) trial for the prevention of colorectal adenomatous polyps, we analyzed plasma concentrations of 74 oxylipins in a subset of participants who received celecoxib (n = 90) or placebo (n = 95). We assessed the effect of celecoxib (with and without low dose aspirin) on circulating oxylipins and systolic blood pressure (SBP). Individual CYP450- and LOX- but not COX-derived metabolites were higher with celecoxib than placebo (P<0.05) and differences were greater among non-aspirin users. LOX derived 5- and 8-HETE were elevated with celecoxib and positively associated with systolic blood pressure (P = 0.011 and P = 0.019 respectively). 20-HETE, a prohypertensive androgen-sensitive CYP450 metabolite was higher with celecoxib absent aspirin and was positively associated with SBP in men (P = 0.040) but not women. Independent of celecoxib or aspirin, LOX derived metabolites from ARA were strongly associated with SBP including 5- and 8-HETE. These findings support oxylipins, particularly the ARA LOX-derived, in blood pressure control and indicate that pharmacologic inhibition of COX-2 has effects on LOX and CYP450 ARA metabolism that contribute to hypertension in some patients.

AB - Drugs that inhibit cyclooxygenase (COX)-2 and the metabolism of arachidonic acid (ARA) to prostaglandin E2 are potent anti-inflammatory agents used widely in the treatment of joint and muscle pain. Despite their benefits, daily use of these drugs has been associated with hypertension, cardiovascular and gastrointestinal toxicities. It is now recognized that ARA is metabolized to a number of bioactive oxygenated lipids (oxylipins) by cyclooxygenase (COX), lipoxygenase (LOX), and cytochrome P450 (CYP450) enzymes. Currently, the contribution of individual variability in ARA metabolism in response to the COX-2 inhibitors and potential adverse effects remains poorly understood. Using patient samples from the randomized, placebo-controlled phase III selenium/celecoxib (Sel/Cel) trial for the prevention of colorectal adenomatous polyps, we analyzed plasma concentrations of 74 oxylipins in a subset of participants who received celecoxib (n = 90) or placebo (n = 95). We assessed the effect of celecoxib (with and without low dose aspirin) on circulating oxylipins and systolic blood pressure (SBP). Individual CYP450- and LOX- but not COX-derived metabolites were higher with celecoxib than placebo (P<0.05) and differences were greater among non-aspirin users. LOX derived 5- and 8-HETE were elevated with celecoxib and positively associated with systolic blood pressure (P = 0.011 and P = 0.019 respectively). 20-HETE, a prohypertensive androgen-sensitive CYP450 metabolite was higher with celecoxib absent aspirin and was positively associated with SBP in men (P = 0.040) but not women. Independent of celecoxib or aspirin, LOX derived metabolites from ARA were strongly associated with SBP including 5- and 8-HETE. These findings support oxylipins, particularly the ARA LOX-derived, in blood pressure control and indicate that pharmacologic inhibition of COX-2 has effects on LOX and CYP450 ARA metabolism that contribute to hypertension in some patients.

UR - http://www.scopus.com/inward/record.url?scp=85046036359&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046036359&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0196398

DO - 10.1371/journal.pone.0196398

M3 - Article

C2 - 29698447

AN - SCOPUS:85046036359

VL - 13

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 4

M1 - e0196398

ER -